An Act amending the act of May 13, 2008 (P.L.139, No.14), known as the Cancer Drug Repository Program Act, further providing for title and short title of act, for definitions, for establishment, for r . . .estocking and dispensing of cancer drugs, for storage, distribution and fees and for immunity; providing for annual report, for list of approved participating pharmacies and for limitations; further providing for regulations; and imposing duties on the State Board of Pharmacy.
Impact
The implementation of HB 69 is designed to create a more structured framework for the management of cancer drugs, potentially improving patient access to these necessary treatments. By establishing regulations and responsibilities for pharmacies involved in the dispensing of these drugs, the bill seeks to enforce standards that could ensure consistent quality and safety throughout the state's healthcare system. An annual report and a list of approved participating pharmacies are mandated to maintain oversight and compliance with the new regulations.
Summary
House Bill 69 aims to enhance the regulation surrounding the handling of cancer drugs within the state. This bill outlines stipulations regarding the title and short title of the act, various definitions related to the legislation, and sets forth guidelines for the establishment, restocking, and dispensing of cancer medications. Additionally, it addresses essential aspects such as storage, distribution, and the fees associated with these processes, reinforcing the responsibilities of the State Board of Pharmacy in overseeing these regulations.
Sentiment
The sentiment surrounding HB 69 appears largely supportive, with a focus on improving the handling of cancer drugs and enhancing patient care. Stakeholders in the healthcare and pharmaceutical sectors may view this bill favorably, as it aims to streamline processes and ensure that critical medications are distributed safely and efficiently. However, there may be underlying concerns regarding the administrative burden placed on pharmacies, particularly smaller operations that might struggle to comply with the new requirements.
Contention
Notable points of contention regarding HB 69 center around the potential impact on pharmacies and their operations. While the bill is framed as a necessary measure for patient safety and drug management, some pharmacy advocates may express concern over the feasibility of implementing these regulations. The requirements for annual reporting and adherence to stringent guidelines could be seen as a challenge, particularly for community pharmacies that may lack the resources to adapt quickly. The bill's support from healthcare professionals contrasts with caution from pharmacy representatives, highlighting a delicate balance between regulation and operational capability.
In quality health care accountability and protection, further providing for definitions and providing for utilization management for stage four, advanced metastatic cancer drugs; and making a repeal.
In duties and powers of boards of school directors, further providing for kindergartens and providing for pre-kindergarten programs; and, in pupils and attendance, further providing for age limits and temporary residence and for definitions.
In preliminary provisions, further providing for definitions; in duties of manufacturers and retailers, further providing for sales prohibition, for registration and for manufacturer plan and reporting; and, in administration, further providing for duties of department, for annual report and for enforcement.
In short title and definitions, further providing for definitions; and, in enforcement and penalties, further providing for enforcement of this act by the secretary and provisions for inspections.
A bill for an act relating to pharmacy benefits managers, pharmacies, prescription drugs, and pharmacy services administrative organizations, and including applicability provisions. (Formerly SSB 1074.) Effective date: 07/01/2025. Applicability date: 07/01/2025.